Compare Recursion vs Terray Therapeutics
Customers evaluate the quality of Recursion's products using the following success metrics.
Overview
Recursion is 11 yrs old and is based in United States.
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.
Terray Therapeutics is 6 yrs old and is based in United States.
Terray Therapeutics is a biotechnology company. The company has developed a novel screening and optimization platform (tArray) to develop invent treatments for intractable causes of human disease. The company is headquartered in Pasadena, California.
Demo Video
Leadership
Christopher Gibson (Founder, Chief Executive Officer)
Eli L Berlin (Founder)
Funding
Investors
NVIDIA, Baillie Gifford & Co.
Two Sigma Ventures, Digitalis Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Recursion has not claimed their profile.
Work for Recursion? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Recursion?
Claim your profile now.
Information not available because Terray Therapeutics has not claimed their profile.
Work for Terray Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Terray Therapeutics?
Claim your profile now.
News & Analysis
Recursion has been mentioned in our research 8 times.
Terray Therapeutics has been mentioned in our research 2 times.
Research Articles
Expert Collections
AI 100
299 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.